OA11662A - Sertraline oral concentrate. - Google Patents

Sertraline oral concentrate. Download PDF

Info

Publication number
OA11662A
OA11662A OA1200100087A OA1200100087A OA11662A OA 11662 A OA11662 A OA 11662A OA 1200100087 A OA1200100087 A OA 1200100087A OA 1200100087 A OA1200100087 A OA 1200100087A OA 11662 A OA11662 A OA 11662A
Authority
OA
OAPI
Prior art keywords
sertraline
concentrate
glycerin
composition
éthanol
Prior art date
Application number
OA1200100087A
Other languages
English (en)
Inventor
Nancy Jane Happer
Gautam Ramchandra Ranade
Willard Mckowan Welch
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22298286&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=OA11662(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of OA11662A publication Critical patent/OA11662A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Psychiatry (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Addiction (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Nutrition Science (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
OA1200100087A 1998-10-13 1999-09-22 Sertraline oral concentrate. OA11662A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US10402498P 1998-10-13 1998-10-13

Publications (1)

Publication Number Publication Date
OA11662A true OA11662A (en) 2004-12-08

Family

ID=22298286

Family Applications (1)

Application Number Title Priority Date Filing Date
OA1200100087A OA11662A (en) 1998-10-13 1999-09-22 Sertraline oral concentrate.

Country Status (46)

Country Link
EP (1) EP1121107B1 (id)
JP (1) JP3792514B2 (id)
KR (1) KR100417200B1 (id)
CN (1) CN1184962C (id)
AP (1) AP2001002119A0 (id)
AR (1) AR014082A1 (id)
AT (1) ATE254453T1 (id)
AU (1) AU766202B2 (id)
BG (1) BG65085B1 (id)
BR (1) BR9914418A (id)
CA (1) CA2346335C (id)
CO (1) CO5150213A1 (id)
CZ (1) CZ20011286A3 (id)
DE (1) DE69912978T2 (id)
DK (1) DK1121107T3 (id)
DZ (1) DZ2913A1 (id)
EA (1) EA003990B1 (id)
EE (1) EE04868B1 (id)
EG (1) EG23818A (id)
ES (1) ES2209490T3 (id)
GC (1) GC0000175A (id)
GE (1) GEP20032969B (id)
GT (1) GT199900171A (id)
HK (1) HK1040199B (id)
HR (1) HRP20010263B1 (id)
HU (1) HUP0104470A3 (id)
ID (1) ID29845A (id)
IS (1) IS2239B (id)
MA (1) MA26698A1 (id)
MY (1) MY122477A (id)
NO (1) NO20011829L (id)
NZ (1) NZ510756A (id)
OA (1) OA11662A (id)
PA (1) PA8483301A1 (id)
PE (1) PE20001108A1 (id)
PL (1) PL348119A1 (id)
PT (1) PT1121107E (id)
PY (1) PY990106A (id)
SK (1) SK4582001A3 (id)
TN (1) TNSN99190A1 (id)
TR (1) TR200101090T2 (id)
TW (1) TWI228043B (id)
UA (1) UA72743C2 (id)
WO (1) WO2000021521A2 (id)
YU (1) YU26401A (id)
ZA (1) ZA200102900B (id)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL211402B1 (pl) 1999-09-03 2012-05-31 Apbi Holdings Zastosowanie dapoksetyny do leczenia lub zwalczania przedwczesnej ejakulacji
US20030086972A1 (en) * 2000-08-09 2003-05-08 Appel Leah E. Hydrogel-driven drug dosage form
WO2004065348A1 (en) 2003-01-23 2004-08-05 Pfizer Products Inc. Pharmaceutically acceptable salts of sertraline and pharmaceutical compositions thereof
WO2005000786A1 (en) 2003-05-23 2005-01-06 Transform Pharmaceuticals, Inc. Sertraline compositions
WO2005034910A1 (en) * 2003-10-08 2005-04-21 Ranbaxy Laboratories Limited Oral liquid pharmaceutical compositions of sertraline
WO2007052152A2 (en) * 2005-11-07 2007-05-10 Aurobindo Pharma Limited Sertraline oral concentrate
US20080268067A1 (en) 2007-03-09 2008-10-30 Llinas Rodolfo R Methods and Compositions for Treating Thalamocortical Dysrhythmia
CN109908354A (zh) * 2017-12-12 2019-06-21 万特制药(海南)有限公司 盐酸舍曲林口服浓缩液及其制备工艺
CN114225038A (zh) * 2021-06-02 2022-03-25 青海春天药用资源科技股份有限公司 酒精和凉味剂组合物在调节性功能、护血管、肝细胞再生、抗肿瘤、提高免疫及睡眠的用途

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4536518A (en) * 1979-11-01 1985-08-20 Pfizer Inc. Antidepressant derivatives of cis-4-phenyl-1,2,3,4-tetrahydro-1-naphthalenamine
ATE96999T1 (de) * 1989-08-30 1993-11-15 Pfizer Verwendung von sertralin zur behandlung von abhaengigkeiten von chemischen stoffen.
US5130338A (en) * 1989-08-30 1992-07-14 Pfizer Inc. Method of treating chemical dependencies using sertraline
US4940731A (en) * 1989-08-30 1990-07-10 Pfizer Inc. Method of treating premature ejaculation using sertraline
US4962128A (en) * 1989-11-02 1990-10-09 Pfizer Inc. Method of treating anxiety-related disorders using sertraline
CA2143070C (en) * 1994-02-22 2001-12-18 Pankaj Modi Oral controlled release liquid suspension pharmaceutical formulation
US5597826A (en) * 1994-09-14 1997-01-28 Pfizer Inc. Compositions containing sertraline and a 5-HT1D receptor agonist or antagonist
SE508372C2 (sv) * 1995-02-13 1998-09-28 Kjell Lindstroem Metod och utrustning för tillförsel eller aspiration av substanser inom gastrointestinalkanalen, avsedd för mätning av farmakokinetiska och fysikalisk-kemiska parametrar
EP0768083B1 (en) * 1995-07-17 2003-03-26 Pfizer Inc. Sertraline for treating post myocardial infarction patients
BR9809712A (pt) * 1997-07-01 2000-07-11 Pfizer Prod Inc Formas de dosagem de sertralina em solução encapsulada de gelatina

Also Published As

Publication number Publication date
AR014082A1 (es) 2001-01-31
HK1040199B (zh) 2005-05-27
MY122477A (en) 2006-04-29
GEP20032969B (en) 2003-05-27
BR9914418A (pt) 2001-06-26
EP1121107A2 (en) 2001-08-08
UA72743C2 (en) 2005-04-15
HRP20010263B1 (en) 2005-04-30
IS2239B (is) 2007-05-15
SK4582001A3 (en) 2002-02-05
DZ2913A1 (fr) 2004-03-01
TWI228043B (en) 2005-02-21
CO5150213A1 (es) 2002-04-29
AU5643699A (en) 2000-05-01
AP2001002119A0 (en) 2001-03-22
KR20010080096A (ko) 2001-08-22
PE20001108A1 (es) 2000-10-26
YU26401A (sh) 2005-07-19
PT1121107E (pt) 2004-02-27
WO2000021521A3 (en) 2000-07-20
CA2346335C (en) 2006-04-18
NZ510756A (en) 2003-05-30
JP3792514B2 (ja) 2006-07-05
ZA200102900B (en) 2002-05-29
MA26698A1 (fr) 2004-12-20
ID29845A (id) 2001-10-18
WO2000021521A2 (en) 2000-04-20
GT199900171A (es) 2001-03-28
IS5906A (is) 2001-03-23
PY990106A (es) 2007-11-01
TNSN99190A1 (fr) 2005-11-10
HUP0104470A2 (en) 2002-08-28
CA2346335A1 (en) 2000-04-20
EA003990B1 (ru) 2003-12-25
NO20011829D0 (no) 2001-04-10
DE69912978T2 (de) 2004-04-22
JP2002527385A (ja) 2002-08-27
EE04868B1 (et) 2007-08-15
HK1040199A1 (en) 2002-05-31
ES2209490T3 (es) 2004-06-16
CN1323202A (zh) 2001-11-21
GC0000175A (en) 2006-03-29
EE200100221A (et) 2002-08-15
PA8483301A1 (es) 2000-09-29
BG65085B1 (bg) 2007-02-28
AU766202B2 (en) 2003-10-09
CZ20011286A3 (cs) 2001-09-12
EA200100285A1 (ru) 2001-10-22
EG23818A (en) 2007-09-19
TR200101090T2 (tr) 2001-12-21
KR100417200B1 (ko) 2004-02-05
ATE254453T1 (de) 2003-12-15
DE69912978D1 (de) 2003-12-24
CN1184962C (zh) 2005-01-19
PL348119A1 (en) 2002-05-06
HUP0104470A3 (en) 2003-12-29
DK1121107T3 (da) 2004-02-23
EP1121107B1 (en) 2003-11-19
HRP20010263A2 (en) 2002-06-30
BG105434A (bg) 2001-12-29
NO20011829L (no) 2001-06-05

Similar Documents

Publication Publication Date Title
CA2333528C (en) A stabilized antihistamine syrup containing aminopolycarboxylic acid as stabilizer
KR101490721B1 (ko) 감칠맛을 가진 디페리프론용 액상 제제
TW201737916A (zh) 口服溶液
US6727283B2 (en) Sertraline oral concentrate
CN110035741B (zh) 包含托莫西汀盐酸盐的口服溶液及其方法
EP1121107B1 (en) Sertraline oral concentrate
JP4959335B2 (ja) メチルフェニデート溶液および関連する投与および製造方法
US20210213024A1 (en) Liquid compositions of aprepitant
CN118892447A (zh) 一种舍曲林口服浓缩液体组合物的制备方法
FR2895260A1 (fr) Nouvelle composition pharmaceutique a base d'huile essentielle pour pulverisation nasale et/ou buccale
WO2005034910A1 (en) Oral liquid pharmaceutical compositions of sertraline
WO2007052152A2 (en) Sertraline oral concentrate
MXPA00011834A (en) A stabilized antihistamine syrup containing aminopolycarboxylic acid as stabilizer